Currently Viewing:
Currently Reading
Judge Dismisses Challenge to 340B Cuts, Final Rule Goes Into Effect
January 03, 2018 – Jaime Rosenberg
Serum Protein Signature Predicts Survival in Patients With Melanoma Receiving Anti–PD-1 Therapy
January 02, 2018 – Jaime Rosenberg
Smokers Willing to Try E-Cigarettes More Successful at Smoking Less, Study Says
December 31, 2017 – Allison Inserro
This Week in Managed Care: December 29, 2017
December 29, 2017
Top 2017 Articles in AJMC®'s Evidence-Based OncologyTM
December 29, 2017 – Surabhi Dangi-Garimella, PhD
5 Events in the Nation's Capital That Drove Managed Care News in 2017
December 29, 2017 – Mary Caffrey
What We're Reading: TV Drug Ads; Kmart Drug Settlement; Evidence-Based Medicine
December 27, 2017 – AJMC Staff
Cancer Gene Profiling Test Can Open Doors to New Targeted Therapies
December 26, 2017 – Jaime Rosenberg
Top 2017 AJMC® Articles Identify Ways to Reduce Costs and Improve Care Outcomes
December 26, 2017 – Laura Joszt

Judge Dismisses Challenge to 340B Cuts, Final Rule Goes Into Effect

Jaime Rosenberg
 A federal judge dismissed a move to block 340B cuts days before CMS’ final rule on it went into effect.
Days before CMS’ final rule on 340B went into effect, a federal judge dismissed a move to block the sharp cut to hospital reimbursements.

The American Hospital Association (AHA), America’s Essential Hospitals, and the Association of American Medical Colleges sued HHS last year to block the 2018 Medicare Outpatient Prospective Payment System rule that would cut $1.6 billion to the Medicare program. US District Judge Rudolph Contreras tossed the case, saying that the suit was premature since the changes hadn’t yet taken effect.

With the cuts now in effect as of January 1, 340B hospitals will receive smaller reimbursements for drugs purchased through the program. Under the old calculation, hospitals received 6% plus the average sales price of the drug; now, hospitals will receive the average sales price minus 22.5%. Rural sole community hospitals, certain cancer hospitals, and children’s hospital will be exempt from the reductions. According to CMS, the savings will be redistributed equally to hospitals covered under the rule. In addition to the cuts, 2 modifiers will be put in place in order to identify whether a drug was purchased under the 340B program.

“Making cuts to the program, like those [the CMS] has put forward, will dramatically threaten access to health care for many communities with vulnerable patients," said Rick Pollack, president and CEO, AHA, in a statement following the ruling. "We are disappointed in this decision from the court and will continue our efforts in the Courts and the Congress to reverse these significant cuts to the 340B program.”

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up